DEINOVE (Euronext Growth Paris: ALDEI), a French biotech firm, pioneer within the exploration and exploitation of bacterial biodiversity to handle the pressing, world problem of antibiotic resistance, pronounces having filed right now a declaration of cessation of funds (“déclaration de cessation des paiements“) and a request for receivership proceedings (“procédure de redressement judiciaire”) of the Company with the Montpellier Commercial Court.
The worker consultant our bodies had been notified prematurely.
The objective of those proceedings is to judge all options that would allow the Company to proceed its business exercise, keep employment, and repay its liabilities underneath the absolute best circumstances, and likewise to provoke a course of to draw buyers inside the framework of a restoration plan by the use of continuation or a sale plan.
The Company will proceed its present actions in the course of the commentary interval.
The Company will inform the monetary markets of the choice of the Montpellier Commercial Court.
Under these circumstances, DEINOVE has requested Euronext to droop the itemizing of its shares (ISIN: FR0010879056) on Euronext Growth from October 28 earlier than the opening of buying and selling, pending the publication of a press launch and till additional discover. Given the uncertainty concerning the result of the steps taken by the Company, the suspension of the itemizing of the Company’s shares (ISIN: FR0010879056) is maintained till additional discover.
ABOUT DEINOVE
DEINOVE is a French biotechnology firm pioneering the exploration of a brand new area of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of uncommon micro organism or nonetheless labeled as uncultivable, it tackles a world well being and financial problem: antimicrobial resistance.
The new therapies found and developed by DEINOVE goal superbugs (microbes which have turn out to be immune to a number of antimicrobials) that trigger life-threatening infections which at the moment are spreading at excessive pace.
This breakthrough strategy gave rise to one of many world’s first specialised micro-biotechnology platforms and a novel assortment of practically 10,000 uncommon strains and hundreds of bacterial extracts. Today, DEINOVE is conducting a number of improvement packages, of which its first antibiotic candidate is at the moment evaluated in a Phase II medical trial in extreme Clostridioides difficile an infection, one of many world’s first emergencies. The Company has additionally developed new bacterial micro-factories that tackle the opposite concern within the race towards antimicrobial resistance: the commercial manufacturing of those uncommon and low concentrated compounds with usually too advanced chemical buildings to be generated by chemical synthesis.
Located on the coronary heart of the Euromedecine park in Montpellier, DEINOVE has been listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056) since 2010. The Company has 45 staff and depends on a community of world-class tutorial, technological, industrial and institutional companions.
CONTACTS
| Investors
Mario Alcaraz Chief Financial and Administrative Officer +33 (0)4 48 19 01 00 Media ATCG Partners +33 (0)9 81 87 46 72 |
- 221028_deinove_pr_request_in-court_rehabilitation_proceedings
